RCD regimen: Difference between revisions
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} ==Overview== {{PAGENAME}} refers to a regimen consisting of rituximab, cyclophosphamide, and dexamethasone used to treat...") |
No edit summary |
||
| Line 2: | Line 2: | ||
{{SI}} | {{SI}} | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
==Overview== | ==Overview== | ||
| Line 9: | Line 8: | ||
==Regimen== | ==Regimen== | ||
{{chemo|R|Rituximab}} | {{chemo|R|Rituximab}} | ||
{{chemo|C|Cyclophosphamide}} | {{chemo|C|Cyclophosphamide}} | ||
{{chemo|D|Dexamethasone}} | {{chemo|D|Dexamethasone}} | ||
==Indications== | ==Indications== | ||
*[[Non-Hodgkin lymphomas]].<ref name="pmid25043930">{{cite journal| author=Perry M, Delarche A, Ribes D, Vergez F, Guilbeau-Frugier C, Laurent C et al.| title=Rituximab-cyclophosphamide-dexamethasone is highly effective in patients with monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas. | journal=Am J Hematol | year= 2014 | volume= 89 | issue= 10 | pages= 969-73 | pmid=25043930 | doi=10.1002/ajh.23798 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25043930 }} </ref> and [[Chronic lymphocytic leukemia]]<ref name="pmid21699387">{{cite journal| author=Michallet AS, Rossignol J, Cazin B, Ysebaert L| title=Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. | journal=Leuk Lymphoma | year= 2011 | volume= 52 | issue= 7 | pages= 1401-3 | pmid=21699387 | doi=10.3109/10428194.2011.591005 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21699387 }} </ref> | *[[Non-Hodgkin lymphomas]].<ref name="pmid25043930">{{cite journal| author=Perry M, Delarche A, Ribes D, Vergez F, Guilbeau-Frugier C, Laurent C et al.| title=Rituximab-cyclophosphamide-dexamethasone is highly effective in patients with monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas. | journal=Am J Hematol | year= 2014 | volume= 89 | issue= 10 | pages= 969-73 | pmid=25043930 | doi=10.1002/ajh.23798 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25043930 }} </ref> and [[Chronic lymphocytic leukemia]]<ref name="pmid21699387">{{cite journal| author=Michallet AS, Rossignol J, Cazin B, Ysebaert L| title=Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. | journal=Leuk Lymphoma | year= 2011 | volume= 52 | issue= 7 | pages= 1401-3 | pmid=21699387 | doi=10.3109/10428194.2011.591005 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21699387 }} </ref> | ||
Latest revision as of 19:05, 30 March 2015
|
WikiDoc Resources for RCD regimen |
|
Articles |
|---|
|
Most recent articles on RCD regimen Most cited articles on RCD regimen |
|
Media |
|
Powerpoint slides on RCD regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on RCD regimen at Clinical Trials.gov Clinical Trials on RCD regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on RCD regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on RCD regimen Discussion groups on RCD regimen Patient Handouts on RCD regimen Directions to Hospitals Treating RCD regimen Risk calculators and risk factors for RCD regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for RCD regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
RCD regimen refers to a regimen consisting of rituximab, cyclophosphamide, and dexamethasone used to treat monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas.[1] and autoimmune cytopenias associated with chronic lymphocytic leukemia.[2]
Regimen
RRituximab
CCyclophosphamide
DDexamethasone
Indications
References
- ↑ 1.0 1.1 Perry M, Delarche A, Ribes D, Vergez F, Guilbeau-Frugier C, Laurent C; et al. (2014). "Rituximab-cyclophosphamide-dexamethasone is highly effective in patients with monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas". Am J Hematol. 89 (10): 969–73. doi:10.1002/ajh.23798. PMID 25043930.
- ↑ 2.0 2.1 Michallet AS, Rossignol J, Cazin B, Ysebaert L (2011). "Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia". Leuk Lymphoma. 52 (7): 1401–3. doi:10.3109/10428194.2011.591005. PMID 21699387.